Presented Posters


QR CODE POSTER ID POSTER
001 P4.4. LONG-TERM SAFETY AND EFFICACY OF MYOBLOC® (RIMABOTULINUMTOXINB) IN THE TREATMENT OF ADULT SIALORRHEA
002 P4.5. MYOBLOC® (RIMABOTULINUMTOXINB) IN THE TREATMENT OF ADULT SIALORRHEA
003 P9.24. THE MOLLII-SUIT®—A NOVEL METHOD USING RECIPROCAL INHIBITION IN CHILDREN WITH CEREBRAL PALSY, GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM IV-V: A 6-MONTH PROSPECTIVE STUDY
004 P3.69. CRYONEUROTOMY AS A NOVEL ADJUNCT TO BOTULINUM TOXIN TREATMENT FOR THE SPASTIC ELBOW: A CASE STUDY
005 P3.27. 5-YEAR FOLLOW-UP AFTER FIRST BOTULINUM TOXIN TYPE A INJECTION IN REAL-LIFE POSTSTROKE SPASTICITY: A SINGLE-CENTER EXPERIENCE IN BARCELONA
006 P7.4. CASE SERIES: TREATMENT OF PHANTOM PAIN USING BOTULINUM TOXIN
007 P9.1. INCOBOTULINUMTOXINA (XEOMIN®) IN DELAYED FACIAL NERVE PALSY DEVELOPING AFTER VESTIBULAR SCHWANNOMA RESECTION
008 P9.2. TREATMENT OF SYNKINESIS AND MASTICATORY MUSCLE HYPERTROPHY WITH INCOBOTULINUMTOXINA (XEOMIN®) IN PATIENTS WITH FACIAL NERVE INJURY AFTER NEUROSURGICAL INTERVENTION
009 P3.41. THE MAXIMUM TOTAL DOSAGE OF ABOBOTULINUMTOXINA FOR MULTILEVEL INJECTIONS IN PATIENTS WITH CEREBRAL PALSY, GMFCS LEVELS IV-V
010 P3.44. BOTULINUM TOXIN IS PRESCRIBED FOR SPASTICITY OR SPASTIC DYSTONIA?
011 P7.6. EFFECTS OF INTRAMUSCULAR BOTULINUM TOXIN INJECTIONS ON HEMIPLEGIC SHOULDER PAIN
012 P3.31. APPROPRIATE DOSAGE (FROM 100 TO 1000 U) OF INCOBOTULINUMTOXINA IN SPASTICITY
013 P4.3. LONG-TERM EFFICACY OF INCOBOTULINUMTOXINA IN THE MANAGEMENT OF SIALORRHEA IN PARKINSON’S DISEASE
014 P9.19. SERVICE EVALUATION OF A PHYSIOTHERAPIST-LED BOTULINUM TOXIN (PLBT) INJECTION THERAPY CLINIC
015 P3.15. A 10-YEAR RETROSPECTIVE REVIEW OF LOWER LIMB BOTULINUM TOXIN INJECTION FOR SPASTICITY
016 P3.12. TREATMENT OF SPASTICITY DUE TO THROMBOTIC BRAIN INJURY WITH INCOBOTULINUMTOXINA: A CASE REPORT
017 P1.25. DUPLICATION OF NEURONAL BINDING DOMAINS DERIVED FROM CLOSTRIDIAL NEUROTOXINS GREATLY ENHANCES INTRANEURONAL DELIVERY OF THERAPEUTICS
018 P3.4. INFLUENCE OF COMBINED USE OF BOTULINUM THERAPY AND ROBOTIC KINESIOTHERAPY ON INDICATORS OF GENERAL MOTOR FUNCTION IN CHILDREN WITH CEREBRAL PALSY
019 P7.12. DOES ONABOTULINUMTOXINA HAVE ANY CENTRAL EFFECTS IN CHRONIC MIGRAINE?
020 P2.7. ABOBOTULINUMTOXINA USING 2 mL DILUTION MAINTAINS DURABLE FUNCTIONAL IMPROVEMENTS ACROSS MULTIPLE TREATMENT CYCLES
021 P2.20. BOTULINUM TOXIN INJECTIONS ARE ABLE TO IMPROVE QUALITY OF LIFE AND DAILY LIVING ACTIVITIES IN PATIENTS WITH UPPER LIMB TREMOR
022 P9.12. SONOGRAPHY-GUIDED INJECTION IN THE NECK MUSCLES: IS IT REALLY THE GOLD STANDARD?
023 P2.21. CLINICAL GUIDANCE OF BOTULINUM TOXIN INJECTIONS IN CERVICAL DYSTONIA: HOW ACCURATE IS NEEDLE PLACEMENT?
024 P1.39. THE TRANSCRIPTOME OF CELL CULTURES DERIVED FROM MUSCLE BIOPSIES OF CONTROLS AND SPASTIC PATIENTS IS AFFECTED BY BOTULINUM TOXIN TYPE A
025 P6.13. CLINICAL ASPECTS OF USING AN UPPER FACE MAPPING SYSTEM FOR ADMINISTRATION OF BOTOX®
026 P2.4. MANAGEMENT ALGORITHM FOR BoNT INJECTIONS WITH ELECTROMYOGRAPHY AND ULTRASOUND GUIDANCE IN CERVICAL DYSTONIA
027 P5.1. PILOT STUDY OF BOTULINUM TOXIN TYPE A UTERINE MUSCLE INJECTION IN THE TREATMENT OF ACUTE DYSMENORRHEA, UTERINE PAIN, AND DEEP DYSPAREUNIA
028 P3.6. TREATMENT DIARY: A TOOL TO OPTIMIZE TREATMENT WITH BOTULINUM TOXIN
029 P3.26. EFFECT OF CHEMODENERVATION AND SERIAL CASTING ON GAIT PARAMETERS IN ACQUIRED BRAIN INJURY PATIENTS WITH UPPER EXTREMITY SPASTICITY
030 P7.10. WHAT BOTULINUM TOXIN TYPE A TELLS US ABOUT THE ROLE OF MYOFASCIAL SYNDROMES IN THE CLINICAL COURSE OF MIGRAINE
031 P3.18. VIDEO AND TEMPORAL SPATIAL PARAMETER ASSESSMENT OF GAIT PRE-/POST- ABOBOTULINUMTOXINA TREATMENT
032 P1.5. THE BINACLE (BINDING AND CLEAVAGE) ASSAY FOR IN VITRO DETERMINATION OF BOTULINUM NEUROTOXIN ACTIVITY
033 P7.8. IMPROVEMENT OF REFRACTORY PELVIC MYOFASCIAL PAIN WITH INCOBOTULINUMTOXINA
034 P3.59. ASSESSMENT OF THE EFFECT OF INCOBOTULINUMTOXINA ON MUSCLE TONE IN CHILDREN WITH SPASTIC DIPLEGIC OR TETRAPLEGIC CEREBRAL PALSY
035 P9.15. ELECTROPHYSIOLOGIC ABNORMALITIES IN IATROGENIC BOTULISM: 2 CASE REPORTS
036 P3.14. SWITCHING FROM ONABOTULINUMTOXINA TO ABOBOTULINUMTOXINA IN CHILDREN WITH CEREBRAL PALSY TREATED FOR SPASTICITY: A RETROSPECTIVE SAFETY EVALUATION
037 P3.13. LONG-TERM IMPROVEMENT ON GMFCS LEVEL OF PATIENTS WITH CEREBRAL PALSY TREATED BY AN INTEGRATED APPROACH OF REPEATED BOTULINUM TOXIN TYPE A INJECTIONS
038 P9.4. BOTULINUM TOXIN IN THE TREATMENT OF RESISTANT DEPRESSIVE DISORDER: COMPARISON OF 2 FACIAL INJECTION SITES
039 P6.1. CONVERSION FROM ONABOTULINUMTOXINA TO INCOBOTULINUMTOXINA FOR AESTHETIC TREATMENTS: A CANADIAN MULTICENTER, REAL-WORLD, RETROSPECTIVE STUDY
040 P9.17. FUNCTIONAL POPLITEAL ARTERY ENTRAPMENT SYNDROME (FPAES) TREATMENT WITH INCOBOTULINUMTOXINA: 3 SUCCESSFUL CLINICAL CASES
041 P3.58. ROLE OF EARLY BOTULINUM TOXIN TYPE A INJECTION IN THE TREATMENT OF PATIENTS WITH POSTSTROKE SPASTICITY: PRELIMINARY RESULTS OF AN OBSERVATIONAL STUDY
042 P3.7. FOCAL SPASTICITY IN MULTIPLE SCLEROSIS: TREATMENT-GOAL ATTAINMENT EVALUATION AFTER BOTULINUM TOXIN TYPE A THERAPY AND PHYSICAL REHABILITATION
043 P4.2. BOTULINUM TOXIN TREATMENT OF SIALORRHEA IN CHILDREN
044 P6.2. SAFETY AND EFFICACY OF ONABOTULINUMTOXINA FOR TREATMENT OF MASSETER MUSCLE HYPERTROPHY: RESULTS FROM A PHASE 2 DOSE-ESCALATION STUDY
045 P5.4. METHODOLOGICAL APPROACHES TO USING BOTULINUM TOXIN FOR VAGINISMUS AND PELVIC PAIN IN WOMEN
046 P2.16. DELAYED AND PROLONGED ARM WEAKNESS AND ATROPHY FOLLOWING BOTULINUM TOXIN INJECTION FOR MUSICIAN’S CRAMP
047 P3.28. BREAKING A DOGMA: HIGH DOSES OF INCOBOTULINUMTOXINA TO TREAT SEVERE LIMB SPASTICITY WITH COMPLEX CLINICAL PATTERNS: A RETROSPECTIVE, MULTICENTER STUDY
048 P6.4. SAFETY OF INCOBOTULINUMTOXINA IN THE TREATMENT OF FACIAL LINES: RESULTS FROM A POOLED ANALYSIS OF RANDOMIZED, PROSPECTIVE, CONTROLLED CLINICAL STUDIES
049 P1.19 COMPARISON OF XEOMIN® TO BOTULINUM NEUROTOXIN TYPE A FORMULATIONS IN ASIA
050 P9.9. INCOBOTULINUMTOXINA: A UNIQUE AND PURE FORMULATION OF BOTULINUM NEUROTOXIN TYPE A FOR USE IN AESTHETIC AND THERAPEUTIC MEDICINE
051 P6.8. EFFICACY OF INCOBOTULINUMTOXINA FOR TREATMENT OF GLABELLAR FROWN LINES IN MALE SUBJECTS: POST HOC ANALYSES FROM RANDOMIZED, DOUBLE-BLIND PIVOTAL STUDIES
052 P1.23. DECREASE IN THERAPEUTIC EFFECT AMONG BOTULINUM NEUROTOXIN TYPE A AGENTS: ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
053 P6.10. EFFICACY AND SAFETY OF INCOBOTULINUMTOXINA IN THE TREATMENT OF UPPER FACIAL LINES: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY
054 P6.11. SAFETY, TOLERABILITY, AND EFFICACY OF REPEAT-DOSE INJECTIONS OF INCOBOTULINUMTOXINA IN THE TREATMENT OF UPPER FACIAL LINES: RESULTS FROM A PROSPECTIVE, OPEN-LABEL, PHASE 3 STUDY
055 P6.16. SAFETY AND EFFICACY OF INCOBOTULINUMTOXINA FOR THE TREATMENT OF UPPER FACIAL LINES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY WITH OPEN-LABEL EXTENSION
056 P6.12. ESCALATING DOSES OF INCOBOTULINUMTOXINA FOR EXTENDED TREATMENT OF GLABELLAR FROWN LINES: SAFETY AND EFFICACY RESULTS FROM A RANDOMIZED, DOUBLE-BLIND STUDY
057 P2.13. EVALUATION OF THE EFFECTIVENESS OF BOTULINUM TOXIN TYPE A IN THE COMPLEX APPROACH TO TREATMENT IN PATIENTS WITH CERVICAL DYSTONIA
058 P2.2. ANTEROCOLLIS POSTURE AND DEEP CERVICAL MUSCLE INJECTIONS WITH BoNT
059 P3.17. INDIVIDUALIZED ONABOTULINUMTOXINA TREATMENT FOR LOWER LIMB SPASTICITY RESULTED IN HIGH PATIENT AND CLINICIAN SATISFACTION IN THE ASPIRE STUDY
060 P3.20. EFFICACY AND SAFETY OF ONABOTULINUMTOXINA FOR TREATMENT OF PEDIATRIC UPPER LIMB SPASTICITY: PRIMARY RESULTS
061 P3.23. INDIVIDUALIZED ONABOTULINUMTOXINA TREATMENT FOR UPPER LIMB SPASTICITY RESULTED IN HIGH PATIENT AND CLINICIAN SATISFACTION IN THE ASPIRE STUDY
062 P3.24. ONABOTULINUMTOXINA TREATMENT UTILIZATION VARIES BY ETIOLOGY OF SPASTICITY, WHILE MAINTAINING HIGH PATIENT AND CLINICIAN SATISFACTION: RESULTS FROM THE ASPIRE STUDY
063 P3.37. EFFICACY AND SAFETY OF ONABOTULINUMTOXINA FOR THE TREATMENT OF PEDIATRIC LOWER LIMB SPASTICITY: PRIMARY RESULTS
064 P5.5. EARLY AND CONSISTENT IMPROVEMENTS IN URINARY SYMPTOMS AND QUALITY OF LIFE WITH ONABOTULINUMTOXINA IN OVERACTIVE BLADDER PATIENTS WITH URINARY INCONTINENCE IN A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 4 TRIAL
065 P2.19. CAMPTOCORMIA TREATMENT WITH INCOBOTULINUMTOXINA (XEOMIN®) IN PATIENTS WITH PARKINSON’S DISEASE
066 P3.39. DETERMINATION OF THE INTRAMUSCULAR MOTOR ENDPOINT FOR EFFECTIVE ADMINISTRATION OF BOTULINUM TOXIN IN THE TREATMENT OF SPASTICITY
067 P9.21. HYPERHIDROSIS: QUALITY OF LIFE AND TREATMENT WITH BOTULINUM TOXIN TYPES A AND B
068 P4.9. INCOBOTULINUMTOXINA INJECTIONS INTO THE SALIVARY GLANDS FOR SIALORRHEA: LUIGI SACCO HOSPITAL EXPERIENCE IN MILAN
069 P9.16. CLINICAL PRESENTATION OF AN OUTBREAK OF FOODBORNE BOTULISM IN SOUTHERN DENMARK
070 P9.20. TREATMENT OF SELF-BITING BEHAVIOUR IN LESCH-NYHAN SYNDROME: USE OF BOTULINUM TOXIN